CStone Pharmaceuticals to Present CS2015 Bispecific Antibody at ACAAI 2025
CStone Pharmaceuticals will present data on its CS2015 bispecific antibody at the 2025 ACAAI Annual Scientific Meeting. This is the first international presentation of CS2015, featuring an ePoster and an oral session. Results are yet to be disclosed, and the company cautions that successful development or marketing of CS2015 is not guaranteed.
CStone Pharmaceuticals has announced that it will present data on its autoimmune and inflammation pipeline asset, CS2015 (OX40L/TSLP bispecific antibody), at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI). This marks the first time CS2015 will be presented at an international academic conference. The presentation will include both an ePoster and an on-site oral session. Results have not yet been presented but are scheduled for disclosure at the upcoming meeting. The company notes there is no guarantee that CS2015 will ultimately be successfully developed or marketed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
